Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function-Reference-Cited by-同舟云学术

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function

Published:2021-08-24 Issue:697 Volume:14 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Salter Alexander I.¹²^ORCID,Rajan Anusha¹²^ORCID,Kennedy Jacob J.²,Ivey Richard G.²^ORCID,Shelby Sarah A.³^ORCID,Leung Isabel¹²,Templeton Megan L.¹²^ORCID,Muhunthan Vishaka¹²^ORCID,Voillet Valentin⁴⁵^ORCID,Sommermeyer Daniel¹²,Whiteaker Jeffrey R.²^ORCID,Gottardo Raphael⁴^ORCID,Veatch Sarah L.³^ORCID,Paulovich Amanda G.²^ORCID,Riddell Stanley R.¹²⁶^ORCID

Affiliation:

1. Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

3. Department of Biophysics, University of Michigan, Ann Arbor, MI 48109, USA.

4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

5. Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, NPC (HCRISA), Cape Town 8001, South Africa.

6. Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.

Abstract

Receptor pathway analysis informs structural modifications to CAR T cells that improve their function.

Funder

National Institutes of Health

American Cancer Society

National Multiple Sclerosis Society Michigan Chapter, Inc.

Lorentz Center

Takeda Canada

Fred Hutchinson Cancer Research Center

University of Washington

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference76 articles.

1. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

2. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

3. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

4. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

5. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs;Science Signaling;2024-07-23

2. Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity;Cell Reports Medicine;2024-07

3. Engineered T Cell Receptor for Cancer Immunotherapy;Biomolecules & Therapeutics;2024-06-07

4. miR‐34a promotes the immunosuppressive function of multiple myeloma‐associated macrophages by dampening the TLR‐9 signaling;Cancer Medicine;2024-06

5. Phospho-mimetic CD3ε variants prevent TCR and CAR signaling;Frontiers in Immunology;2024-05-08